For the quarter ended June 2026, Boston Scientific (BSX) reported revenue of $5.44 billion, up 7.5% over the same period last year. EPS came in at $0.86, compared to $0.75 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $5.38 billion, representing a surprise of +1.07%. The company delivered an EPS surprise of +3.61%, with the consensus EPS estimate being $0.83.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Boston Scientific performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

  • Geographic Revenue- Rest of the World: $2.02 billion compared to the $1.98 billion average estimate based on two analysts. The reported number represents a change of +9.8% year over year.
  • Geographic Revenue- U.S.: $3.43 billion versus $3.39 billion estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +6.3% change.
  • Net Sales- MedSurg- Worldwide: $1.82 billion compared to the $1.8 billion average estimate based on five analysts. The reported number represents a change of +5.9% year over year.
  • Net Sales- Cardiovascular- Worldwide: $3.62 billion versus $3.6 billion estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +8.3% change.
  • Net Sales- MedSurg- Neuromodulation- Worldwide: $341 million versus $335.33 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +12.5% change.
  • Net Sales- MedSurg- Endoscopy- Worldwide: $793 million versus $774.1 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +7.6% change.
  • Net Sales- MedSurg- Urology- Worldwide: $684 million compared to the $694.74 million average estimate based on four analysts. The reported number represents a change of +1.2% year over year.
  • Net Sales- Cardiovascular- Cardiac Rhythm Management (CRM)- Worldwide: $585 million compared to the $601.79 million average estimate based on three analysts. The reported number represents a change of -0.9% year over year.
  • Net Sales- Cardiovascular- Interventional Cardiology & Vascular Therapies- Worldwide: $1.33 billion compared to the $1.26 billion average estimate based on three analysts. The reported number represents a change of +82.4% year over year.
  • Net Sales- Cardiovascular- Watchman- Worldwide: $507 million compared to the $535.88 million average estimate based on three analysts. The reported number represents a change of +4.3% year over year.
  • Net Sales- Cardiovascular- Electrophysiology- Worldwide: $916 million versus $923.15 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +9.1% change.
  • Net sales- Interventional Oncology & Embolization- Worldwide: 283.00 2 versus the two-analyst average estimate of 274.38 2.

View all Key Company Metrics for Boston Scientific here>>>

Shares of Boston Scientific have returned +7.9% over the past month versus the Zacks S&P 500 composite's +1.9% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.

Free: See Our Top Stock And 4 Runners Up

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

 

Boston Scientific Corporation (BSX): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research